Table 2.
Numbers of patients treated with a cellular therapy in Europe 2020 by indication, donor type and cell source.
| Number of patients | DLI | CART | MSC | NK cells | Selected/expanded T cells or CIK | Regulatory T cells (TREGS) | Genetically modified T cells | Dendritic cells | Expanded CD34+ cells | Genetically modified CD34+ cells | Other | Total excl DLI | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | allo | auto | |
| GvHD | 343 | 1 | 24 | 1 | 1 | 369 | 1 | ||||||||||||||||
| Graft enhancement | 31 | 2 | 6 | 13 | 5 | 13 | 1 | 159 | 35 | 223 | 42 | ||||||||||||
| Autoimmune dis. | 22 | 9 | 22 | 9 | |||||||||||||||||||
| Genetic disease | 1 | 8 | 1 | 8 | |||||||||||||||||||
| Infection | 17 | 147 | 2 | 1 | 21 | 1 | 188 | 1 | |||||||||||||||
| Malignancy—ALL | 25 | 291 | 1 | 2 | 41 | 4 | 3 | 72 | 295 | ||||||||||||||
| Malignancy—HL/NHL | 2 | 1435 | 1 | 7 | 4 | 2 | 1 | 16 | 1436 | ||||||||||||||
| Malignancy—Other | 2 | 120 | 14 | 7 | 36 | 5 | 5 | 5 | 26 | 5 | 8 | 4 | 41 | 196 | |||||||||
| DLI for graft enhancement/failure | 728 | 0 | 0 | ||||||||||||||||||||
| DLI for residual disease | 482 | 0 | 0 | ||||||||||||||||||||
| DLI for relapse | 1265 | 0 | 0 | ||||||||||||||||||||
| DLI per protocol | 580 | 0 | 0 | ||||||||||||||||||||
| Total | 3055 | 29 | 1846 | 414 | 12 | 23 | 0 | 215 | 41 | 29 | 0 | 7 | 5 | 6 | 30 | 13 | 0 | 3 | 13 | 193 | 41 | 932 | 1988 |